The use of Next-Generation Sequencing (NGS) has revolutionized cancer detection by providing a high-throughput and increasingly cost-efficient technology. Healthcare institutions are adopting NGS to characterize multiple cancer-associated alterations in routine diagnostics.
Hundreds of thousands of people of all ages are diagnosed with hematological malignancies such as Leukemia worldwide. To improve patient’s quality of life, and accelerate the disease management it is essential for healthcare professionals to adopt solutions that ensure fast and precise diagnosis.
SOPHiA GENETICS offers genomic applications that are expertly designed to accurately characterize the complex mutational landscape of the major hematological disorders associated with leukemias, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN).
In the first part of this webinar, Dr. Alexander Kurze will present the current limitations and challenges in hematological genomic testing and how to overcome those hurdles by adopting SOPHiA’s solutions.
Then, he will present the clinical-grade performance of these solutions matching diagnostic requirements.
In the second part of this webinar, Dr. Emily Paul will describe the clinical utility of the SOPHiA platform for advance detection and characterization of pathogenic alterations associated with hematological disorders.
Dr. Alexander Kurze holds a PhD in Biochemistry from the University of Oxford, UK. After a successful career in academia, he joined Thermo Fisher Scientific as a Field Application Scientist for NGS and works now at SOPHiA GENETICS as a global Clinical Application Product Manager for liquid tumors.
Dr. Emily Paul holds a PhD in Biomedical Sciences from the University at Albany -SUNY. After a successful career in academia, she joined SOPHiA GENETICS and works as the Subject Matter Expert Manager in North America.